AlzeCure shares hit highest since 2022 on $2.2 bln Alzheimer’s drug licensing deal

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop